Heart Preservation Using Continuous Ex Vivo Perfusion Improves Viability and Functional Recovery

Ozeki, Toshinaga; Kwon, Michael H.; Gu, Jun; Collins, Michael J.; Brassil, J; Miller, Michael B.; Gullapalli, Rao P.; Zhuo, Jiachen; Pierson, Richard N.; Griffith, Bartley P.; Poston, Robert

doi:10.1253/circj.71.153

Cited by 67 publications

(52 citation statements)

References 38 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuous ex vivo heart perfusion demonstrated a beneficial influence on aerobic metabolism during the preservation of the donor heart by maintaining cell integrity and vital cell function [17]. Another advantage of continuous coronary organ perfusion is related to the ongoing washout of anaerobic metabolic products, the result of extended ischemia of the organ [18].…”

Section: Ex Vivo Pretransplant Organ Reconditioningmentioning

confidence: 99%

Ex vivo Approach to Treat Failing Organs: Expanding the Limits

Ciubotaru

Haverich

2014

Eur Surg Res

View full text Add to dashboard Cite

Background: Advanced organ failure is often classified as an end-stage disease where the treatment options are limited only to transplantation. As an alternative, different attempts have been undertaken to improve the outcome of the treatment of failing organs by using targeted ex vivo approaches. This may solve the issue of organ shortage by treating the donor organs before transplantation and the number of patients requiring transplantation may also be reduced by applying extensive ex vivo treatment followed by autotransplantation. Methods: We performed a literature review of PubMed and included articles published between 1962 and 2013. The following keywords were used (and; or): ex vivo, therapy, surgery, organ perfusion and autotransplantation. This review includes specific methods and attempts related to ex vivo organ perfusion and preservation, temporary life support systems, surgical and other therapeutic approaches, and diagnostic methods applied ex vivo to an isolated organ. Results: For the practical clinical use of ex vivo therapies, we could identify three major directions: (1) ex vivo pretransplant organ reconditioning, (2) ex vivo surgery and (3) ex vivo medical treatment. Different attempts have been made worldwide in the above-mentioned areas focusing on ex vivo organ preservation and treatment. We summarize in the present review the developments in the field of ex vivo organ recovery and evaluate the possibilities of combining and applying different technologies such as organ perfusion and storage, ex vivo exact topographical diagnosis, ex vivo locoregional medical treatment and ex vivo surgical correction. Conclusion: Ex vivo therapies open new horizons in the treatment of end-stage organ pathologies.

show abstract

Section: Ex Vivo Pretransplant Organ Reconditioningmentioning

confidence: 99%

Ex vivo Approach to Treat Failing Organs: Expanding the Limits

Ciubotaru

Haverich

2014

Eur Surg Res

View full text Add to dashboard Cite

show abstract

“…Grafts preserved with MP also had a higher tissue pH and ATP levels suggestive of less oxidative damage and energy depletion. 114 …”

Section: Benefits Of Machine Perfusionmentioning

confidence: 99%

Advances in Machine Perfusion Graft Viability Assessment in Kidney, Liver, Pancreas, Lung, and Heart Transplant

Balfoussia

Yerrakalva²,

Hamaoui³

et al. 2012

Exp Clin Transplant

View full text Add to dashboard Cite

“…However, ideas and methods for continuous perfusion during the hypothermic period are well established, e.g., continuous hypothermic perfusion of the heart was first applied only a year after the first successful human heart transplant [81]. Since then it shown that it is possible to keep large mammalian hearts viable for up to 48 hours in baboons and swine [82], as well as improve function compared to non-perfused hearts [83]. While continuous hypothermic perfusion is not used clinically with heart transplantation, it should be noted that the Organ Care System (Transmedics, Andover, MA) gained investigational device exemption status in 2007, and a clinical trial is currently underway.…”

Section: Protocolsmentioning

confidence: 99%